Belgian biotech ThromboGenics has announced it will change its name to Oxurion in the next few weeks. The stock ticker symbol will change to OXUR.
Chief executive Patrik De Haes said: “The new name, Oxurion, is designed to better reflect our ambition to deliver best in class therapies for back of the eye disorders,” and “we are also expanding our drug development efforts into new back of the eye indications where there is clear need for improved therapeutic options.”
Source: The Pharma Letter
Hybrid closed-loop systems rely on an algorithm to first analyze real-time blood sugar readings from a continuous glucose monitor, then use the results to adjust an insulin pump’s output as needed throughout the day. In this case, the algorithm was developed by Diabeloop, the CGM is a Dexcom G6 sensor, and the insulin pump comes from ViCentra.
Boehringer Ingelheim has acquired bacterial cancer therapy company T3 Pharmaceuticals in a deal that could be worth up to 450 million Swiss francs ($508 million). The addition of Allschwil, Switzerland-based T3 will “significantly expand” the German drugmaker’s immuno-oncology pipeline and aligns with some of the company’s existing R&D programs.
EuroAPI has completed the acquisition of BianoGMP, a contract development and manufacturing organization (CDMO) specializing in oligonucleotides. The acquisition, announced in August, further differentiates its value proposition to support a broader client base across the whole oligonucleotide development continuum, from research to commercialization, EuroAPI said.
